Claim OwnershipBioTech Nation ... with Dr. Moira Gunn
Subscribed: 425Played: 3,939
Subscribe
© Tech Nation Media
Description
Welcome to BIOTECH NATION !!! With understandable interviews requiring no background in science, BTN attracts a wide global audience. From everyday people looking for hope in treatments in development, to bioentrepreneurs interested in the experience of their fellow travelers, to venture capitalists looking for possibilities in cutting-edge breakthroughs, to scientists simply interested in the work of others, BioTech Nation is the voice of human endeavor, driving science to new realities for everyone. These interviews are drawn directly from the public radio program, "Tech Nation", which also can be heard in numerous global radio and podcasting venues.
155 Episodes
Reverse
This is the 2026 BioTech Nation "5": Five Companies Ready to Make a Difference. We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco. Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5On this episode of BioTech Nation, Moira speaks with Dr. Barry Quart, CEO of Connect Biopharma, about a new fast-acting treatment for inflammatory conditions like Asthma, COPD, and Eczema. Often, these conditions can be managed with anti-inflammatory therapeutics like Dupixent, but even then, sudden and painful flare-ups can occur. We take a closer look at a new anti-inflammatory in late-stage development which starts working quickly, much needed when those flare-ups develop. For more information about BioTech Nation and the companies featured here, visit: TechNation.com
This is the 2026 BioTech Nation "5": Five Companies Ready to Make a Difference. We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco. Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5On this episode of BioTech Nation...Dr. Harry Selker & Dr. Atul Deshpande of Immediate Therapeutics speak with Moira about a new treatment that could be administered to heart attack patients right away...potentially before they even arrive at the hospital. Already successfully tested in Phase 2, it’s ready to go into final pivotal trials in Ambulances and Emergency Rooms.For more information about BioTech Nation and the companies featured here, visit: TechNation.com
This is the 2026 BioTech Nation "5": Five Companies Ready to Make a Difference. We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco. Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5On this episode of BioTech Nation...Ever wonder what makes opioids so addictive? Moira speaks with Ketan Mehta, Founder and CEO of Tris Pharma, about opioid-induced euphoria...and an opioid that's actually meant to suppress this response. For more information about BioTech Nation and the companies featured here, visit: TechNation.com
This is the 2026 BioTech Nation "5": Five Companies Ready to Make a Difference. We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco. Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5On this episode of BioTech Nation...Moira speaks with Neil Klompas of Augurex Life Sciences, about a new diagnostic for chronic, long-term back pain that pinpoints a form of arthritis. On average, patients with this condition could go 7-10 years without a diagnosis, having to first eliminate everything else with an odyssey of tests. Now, a simple blood test could be the answer.For more information about BioTech Nation and the companies featured here, visit: TechNation.com
This is the 2026 BioTech Nation "5": Five Companies Ready to Make a Difference. We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco. Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5On this episode of BioTech Nation: Can cancer cells be turned against themselves? Moira speaks with Cyriac Roeding and Dr. David Suhy, Co-Founders of Earli, about an innovative new approach to treating solid tumor cancer. They discuss their effort to turn the cancer cells inside solid tumors into factories that produce their own cancer-fighting therapeutic.For more information about BioTech Nation and the companies featured here, visit: TechNation.com
This week on Biotech Nation, Dr. Martin Borch Jensen and Dr. Francisco LePort from Gordian Biotechnology share a bold new approach to fighting diseases of aging before they take hold. Instead of testing one drug at a time, their technology allows scientists to test hundreds of potential treatments at once, making drug discovery faster and more precise. This could change how we treat conditions like arthritis, heart failure, and fatty liver disease.
This week on BioTech Nation, we explore what happens when your immune system overreacts. Professor Niels Riedemann, CEO of InflaRx, explains how the body’s defense system can sometimes cause more harm than good, leading to serious conditions like rheumatoid arthritis, severe COVID-19, and lung failure. Learn how InflaRx is developing treatments to calm the immune system and why their breakthrough drug is getting attention from U.S. health agencies.
This week on Biotech Nation, Dr. Ari Azhir, Founder and CEO of Neuvivo, shares the incredible journey of an ALS drug that was once abandoned, but is now making its way toward FDA approval. After two failed phase two trials, the drug was left behind until Dr. Azhir and her team discovered a crucial mistake in the trial data. Now with new insights and groundbreaking survival results, Neuvivo is giving hope to ALS patients and exploring its potential for other neurodegenerative diseases like Huntington’s and Alzheimer’s.
This week on BioTech Nation, Bruin Biometrics CEO Martin Burns talks about a new diagnostic tool being used to detect and prevent potentially fatal bedsores in their earliest stages.
For years, we've all turned to Google to self-diagnose every cough, rash, and weird pain. Dr. Daniel Kraft says the shift is happening, from Dr. Google to Dr. ChatGPT.
This week on Biotech Nation, Dr. Lincoln Nadauld shares how Culmination Bio is using 9 million preserved tissue samples and decades of patient data to improve how we understand and treat diseases. From discovering patterns in cancer treatments to exploring breakthroughs in heart and autoimmune diseases, this unique approach is changing medicine.
What if we could fix the gene that causes dementia? In this episode, Aviado Bio CEO Lisa Deschamps tells us how her team is working to correct the gene driving many cases of frontotemporal dementia.
What if you could tune your DNA to fix any mistakes? Dr. Derek Jantz from Tune Therapeutics talks about tuning DNA, not just with humans, but stopping the Hepatitis B virus in its tracks.
Imagine a world where the toughest wounds heal twice as fast, and patients get their lives back sooner than anyone thought possible. Dr. Ned Swanson, the President and Chief Medical Officer of Polarity Bio, tells us about their approach to healing serious, hard-to-treat skin wounds. In early trials, it's twice as effective as the current treatment for diabetic foot ulcers.
40% of all rheumatoid arthritis patients do not respond to any of the current drugs. Rob Armstrong, CEO of Artax Biopharma, aims to bring new hope for those patients who've been left without effective treatment options.
Can you imagine parents expecting a baby, going in for an ultrasound, and finding out that their baby is missing the heart's left ventricle? This week on BioTech Nation, Dr. Joshua Hare, Co-Founder and Chief Scientific Officer of Longeveron, talks about how they are testing the use of stem cells to treat babies born with a serious congenital heart defect.
This week on BioTech Nation, Dr. Jeff Stein, President & CEO of Cidara Therapeutics, brings up promising news about a new approach to flu shots.
Dr. Marc Salzberg, CEO & Chief Medical Officer of Airway Therapeutics, talks about what they are doing to help preterm babies. It may all boil down to delivering these babies a single protein as soon as they are born.
Dr. Avak Kahvejian, Founding CEO of Cellarity, explains their new approach to discovering drugs by using AI to look at how cells behave as a whole, rather than focusing on one part of the problem. This approach could lead to faster development of better treatments, such as a pill for sickle cell disease.
This week on Biotech Nation, Paul Hastings, CEO of Nkarta and former chair of BIO—the Biotechnology Innovation Organization—discusses the impact of cuts to research funding and stepping away from recommending vaccines—what this means for you and the biotech industry.
Comments
Download from Google Play
Download from App Store
United States